Longboard Pharmaceuticals

NEWS

Pictured: Bar and line graphs showing increasing t

Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering

Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news.

January 3, 2024

2 min read

Tristan Manalac

IN THE PRESS

Drug Development

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

January 2, 2024

12 min read

Drug Development

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

January 1, 2024

7 min read

Drug Development

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

November 29, 2023

7 min read

Biotech Beach

Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 3, 2023

6 min read

Business

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 2, 2023

11 min read

Biotech Beach

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

November 1, 2023

5 min read

Biotech Beach

Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023

October 5, 2023

7 min read

Biotech Beach

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023

September 19, 2023

7 min read

Biotech Beach

Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

August 31, 2023

3 min read

Biotech Beach

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

August 30, 2023

4 min read

JOBS